FDA approves 1st-of-its-kind hepatitis B treatment amid vaccine policy battle
The FDA has approved GSK’s Hibsago (bepirovirsen), the first FDA-approved antisense oligonucleotide for chronic hepatitis B, as federal hepatitis B vaccination policy faces continued scrutiny. The drug is approved in combination with existing antiviral therapy for certain adults without cirrhosis who have been taking HBV antiviral therapy for at least six months, have suppressed HBV […] The post FDA approves 1st-of-its-kind hepatitis B treatment amid vaccine policy battle appeared f...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.